A phase II, randomized, open-label study to assess the efficacy of extended-dose schedule administration of darbepoetin alfa in cancer patients with chemotherapy-induced anemia

Lee Schwartzberg, Timothy Rearden, Lorrin Yee, Barry Mirtsching, Veena Charu, Hung Lam, Tom Lillie, Ronald Burkes, Peter Silberstein

Research output: Contribution to journalArticle

1 Scopus citations

Fingerprint Dive into the research topics of 'A phase II, randomized, open-label study to assess the efficacy of extended-dose schedule administration of darbepoetin alfa in cancer patients with chemotherapy-induced anemia'. Together they form a unique fingerprint.